Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data on one of these agents, the TAAR1 agonist ulotaront, are summarized.
The Journal of Clinical Psychiatry
Insights February 17, 2022
Emerging Treatments in Schizophrenia Video
Vol 87 • 2026 • Number 2
Read the Current Issue
Original Research
CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial
Original Research
Neuropsychiatric Symptom Clusters and Brain Structure in Alzheimer’s Disease
Systematic Review
Thirty Years of the Diagnostic Criteria for Psychosomatic Research
Original Research
Efficacy of Olanzapine/Samidorphan on Negative Symptoms
Original Research
Comparing Risk Prediction for Suicide Attempts and Deaths After Emergency Department Visits
Clinical and Practical Psychopharmacology
Insomnia, Sleep, and the Use of Sedative-Hypnotic Drugs: Practical Notes
Related Articles
Insights
Cognitive Impairment, Reward Pathways and Treatment Challenges in Schizophrenia Video
January 14, 2023
Evaluating different domains of negative symptoms separately to better understand their impact on functional outcomes, particularly cognitive symptoms, is important in the treatment of patients with schizophrenia, especially intervening...
Insights
Sequencing Therapy in the Treatment of Schizophrenia Video
January 14, 2023
Balancing and optimizing safety and efficacy when treating patients with schizophrenia can be challenging. New approaches to treatment may impact symptoms more effectively and contribute to better adherence. Sequencing,...
